Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection

About this update from Vcanbio Cell & Gene Engineering Corp., Ltd. Class A

Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Vcanbio Cell & Gene Engineering Corp., Ltd. Class A